Capricor Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Capricor Therapeutics' CAP-1002 Shows Promise in DMD Treatment: Buy Rating Affirmed Following Positive Clinical Trials
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer
Capricorn Therapeutics (CAPR.US) was first covered by Oppenheimer, which gave it an superior market rating and a target price of $14.00.
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments
Ladenburg Thalmann: Maintaining the Capricorn Therapeutics (CAPR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $25.00.
Capricor Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Stereotaxis (STXS), Capricor Therapeutics (CAPR)
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
Capricor Therapeutics Analyst Ratings
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Capricor Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), CVRx (CVRX) and Capricor Therapeutics (CAPR)